MetaboStem is developing breakthrough oncology drugs directed to Cancer Stem Cells (CSC), the most dangerous and deadliest class of cancer cells.It’s a spin-off of the Catalan Institute of Oncology, which affords it with a unique capacity to accelerate development of oncology clinical research.
MetaboStem aims to rapidly advance its anti-CSC drugs through completion of clinical proof-of-efficacy (Phase2a), and then seek a total or partial exit.